Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Cigna Group
CIHealthcareGenerated Aug 19, 2026, 09:41 PM UTC
CI (Cigna Group) analytical snapshot. Revenue grew +11.2% YoY to $274.90B. 5-year revenue CAGR +9.6%; 10y CAGR +23.9%. Net margin at 2.17% (contracting ▼). Market cap $73.31B at $277.45 per share. Trailing P/E 12.51, P/S 0.27, P/B 1.72. EV/Operating income ≈ 11.58 (EV $106.54B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -11 (data confidence 80%). Descriptive analytics from public filings — not investment advice.
Free SEC analysis
— computed from SEC filings, free to readFilings & Ownership
Latest annual report (10-K) filed Feb 26, 2026. Latest quarterly report (10-Q) filed Jul 30, 2026. 20 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 26, 2026.
- Latest quarterly report (10-Q) filed Jul 30, 2026.
- 20 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Cigna Group; broad institutional reporting.
- Recent filers include XY Capital Ltd, TAM Capital Management Inc., TAM Capital Management Inc..
- 3 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 3 recent 13G passive institutional ownership notices.
| Filer | Form | Filed |
|---|---|---|
| XY Capital Ltd | 13F-HR | Aug 5, 2024 |
| TAM Capital Management Inc. | 13F-HR | Aug 15, 2025 |
| TAM Capital Management Inc. | 13F-HR | Nov 14, 2025 |
| XY Capital Ltd | 13F-HR | May 12, 2026 |
| TAM Capital Management Inc. | 13F-HR | May 16, 2025 |
| Date | Form | Description |
|---|---|---|
| Jul 30, 2026 | 8-K | 8-K |
| May 13, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Apr 27, 2026 | 8-K | 8-K |
| Mar 3, 2026 | 8-K | 8-K |
| Feb 27, 2026 | 8-K | 8-K |
| Feb 5, 2026 | 8-K | 8-K |
| Nov 18, 2025 | 8-K | 8-K |
SEC Filing Deep-Analysis
2 risk signal(s), 1 positive signal(s) detected from XBRL filing diff analysis. 2 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- Earnings-cash flow divergence: Net income grew +73.5% while operating cash flow declined -7.4%. This divergence may indicate accrual-based earnings inflation — non-cash gains, aggressive revenue recognition, or working capital absorption. The accrual ratio (NI − OCF) is deteriorating.
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 2 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 1.61x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: 2 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 4 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- Ongoing high-severity risk language: Restatement of financial statements.
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $247.12B | $274.90B | $27.78B | +11.2% |
| Operating income | $9.42B | $9.20B | $-217.0M | -2.3% |
| Net income | $3.43B | $5.96B | $2.52B | +73.5% |
| Operating cash flow | $10.36B | $9.60B | $-762.0M | -7.4% |
| Capex | $528.0M | $1.05B | $522.0M | +98.9% |
| Total assets | $155.88B | $157.92B | $2.04B | +1.3% |
| Total liabilities | $114.64B | $116.05B | $1.41B | +1.2% |
| Cash & equivalents | $7.55B | $7.68B | $126.0M | +1.7% |
| Stockholders equity | $41.03B | $41.71B | $680.0M | +1.7% |
| Inventory | $6.69B | $7.34B | $646.0M | +9.7% |
| SG&A expense | $14.84B | $14.62B | $-227.0M | -1.5% |
| Interest expense | $1.50B | $1.40B | $-100.0M | -6.7% |
| Type | Concepts |
|---|---|
| Added | CashSurrenderValueDuePolicyholdersAmount, PolicyholderAccountBalanceNetAmountAtRisk, PolicyholderAccountBalanceWeightedAverageCreditingRate, PolicyholderContractDeposits |
| Removed | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment, AllocatedShareBasedCompensationExpense, AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries, AssetsHeldByInsuranceRegulators, AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent, CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations, CommonStockDividendsPerShareCashPaid, CommonStockSharesOutstanding, ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest, CurrentFederalTaxExpenseBenefit |
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Restatement of financial statements | high | 2 | 2 | Ongoing |
| Impairment charge | medium | 5 | 2 | Ongoing |
| Restructuring | medium | 5 | 2 | Ongoing |
| Off-balance sheet arrangements | medium | 5 | 2 | Ongoing |
| Related party transactions | low | 1 | 0 | NEW |
Fundamentals
Revenue grew +11.2% YoY to $274.90B. 5-year revenue CAGR +9.6%; 10y CAGR +23.9%. Net margin at 2.17% (contracting ▼).
- Revenue grew +11.2% YoY to $274.90B.
- 5-year revenue CAGR +9.6%; 10y CAGR +23.9%.
- Net margin at 2.17% (contracting ▼).
- Return on equity 14.28%, ROA 3.77%, ROIC 22.06%.
- Gross margin 0.00%, operating margin 3.35%.
- Net income up ▲ +73.5% YoY.
- Debt/equity 0.93, current ratio 0.85, net debt $33.23B.
- Asset turnover 1.75 — capital efficiency.
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2024 | $247.12B | +26.6% | 0.00 | 3.81 | 1.39 | — | 8.37 |
| 2025 | $274.90B | +11.2% | 0.00 | 3.35 | 2.17 | — | 14.28 |
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Sep 30, 2024 | $63.69B | +29.9% | — | — |
| Mar 31, 2025 | $65.50B | +14.4% | +2.8% | 2.02% |
| Jun 30, 2025 | $67.18B | +11.0% | +2.6% | 2.28% |
| Sep 30, 2025 | $69.75B | +9.5% | +3.8% | — |
| Mar 31, 2026 | $68.49B | +4.6% | -1.8% | 2.41% |
| Jun 30, 2026 | $71.67B | +6.7% | +4.6% | 2.32% |
Pro analysis — preview
— score, signals & key metrics shown; full reasoning lockedValuation
Market cap $73.31B at $277.45 per share. Trailing P/E 12.51, P/S 0.27, P/B 1.72. EV/Operating income ≈ 11.58 (EV $106.54B).
- Market cap $73.31B at $277.45 per share.
Price & Technicals
Price $277.45 — downtrend (below 200-DMA); 1-month momentum negative. RSI(14) 42.01.
- Price $277.45 — downtrend (below 200-DMA); 1-month momentum negative.
Macro & Rates
Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.
- Market regime: Risk-on · Supportive.
Risk Scorecard
Composite risk Elevated. Leverage debt/equity 0.93 (moderate). Liquidity current ratio 0.85 (stretched).
- Composite risk: Elevated.
See the full picture behind every stock
Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.
3 sections free · 4 Pro previews · composite -11
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Cigna Group is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Analytical read
deterministic previewMarket regime: Risk-on · Supportive..
Peer comparison
Defensive groupHow CI stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| DexCom Inc. DXCM | 21 | Neutral |
| Bristol-Myers Squibb BMY | 19 | Neutral |
| Eli Lilly & Co. LLY | 17 | Neutral |
| HCA Healthcare HCA | 9 | Neutral |
| Gilead Sciences GILD | 8 | Neutral |
| Johnson & Johnson JNJ | 8 | Neutral |
| Abbott Laboratories ABT | 7 | Neutral |
| Biogen Inc. BIIB | 7 | Neutral |
| Intuitive Surgical Inc. ISRG | 7 | Neutral |
| Coca-Cola Co. KO | 6 | Neutral |
| Zoetis Inc. ZTS | 6 | Neutral |
| Thermo Fisher Scientific TMO | 3 | Neutral |
| Regeneron Pharmaceuticals REGN | 3 | Neutral |
| Danaher Corp. DHR | 1 | Neutral |
| Merck & Co. MRK | 0 | Neutral |
| Illumina Inc. ILMN | 0 | Neutral |
| Colgate-Palmolive CL | -2 | Neutral |
| Vertex Pharmaceuticals VRTX | -2 | Neutral |
| AbbVie Inc. ABBV | -5 | Neutral |
| Procter & Gamble PG | -7 | Neutral |
| CVS Health Corp. CVS | -8 | Neutral |
| Mondelez International MDLZ | -10 | Neutral |
| Amgen Inc. AMGN | -10 | Neutral |
| Cigna Group CI● you | -11 | Neutral |
| Kroger Co. KR | -12 | Neutral |
| Costco Wholesale COST | -14 | Neutral |
| Walmart Inc. WMT | -14 | Neutral |
| Pfizer Inc. PFE | -15 | Neutral |
| PepsiCo Inc. PEP | -16 | Neutral |
| Sysco Corp. SYY | -16 | Neutral |
| Hershey Co. HSY | -17 | Neutral |
| Kimberly-Clark Corp. KMB | -18 | Neutral |
| Moderna Inc. MRNA | -21 | Neutral |
| UnitedHealth Group UNH | -25 | Neutral |